Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Long-Term Debt Repayments (2016 - 2024)

NovaBay Pharmaceuticals (NBY) has disclosed Long-Term Debt Repayments for 9 consecutive years, with $507000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $507000.0 in Q1 2025 year-over-year; TTM through Sep 2025 was $2.5 million, a 1881.75% increase, with the full-year FY2024 number at $2.0 million, up 35.01% from a year prior.
  • Long-Term Debt Repayments was $507000.0 for Q1 2025 at NovaBay Pharmaceuticals, down from $2.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $2.0 million in Q4 2024 to a low of -$1.2 million in Q3 2024.
  • A 3-year average of $484714.3 and a median of $507000.0 in 2025 define the central range for Long-Term Debt Repayments.
  • Biggest YoY gain for Long-Term Debt Repayments was 1479.37% in 2024; the steepest drop was 307.97% in 2024.
  • NovaBay Pharmaceuticals' Long-Term Debt Repayments stood at $126000.0 in 2023, then skyrocketed by 1479.37% to $2.0 million in 2024, then tumbled by 74.52% to $507000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Long-Term Debt Repayments are $507000.0 (Q1 2025), $2.0 million (Q4 2024), and -$1.2 million (Q3 2024).